- Home
- MDU vs AKRO Comparison
MDU vs AKRO Comparison
Compare MDU & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDU
- AKRO
- Stock Information
- Founded
- MDU 1924
- AKRO 2017
- Country
- MDU United States
- AKRO United States
- Employees
- MDU N/A
- AKRO N/A
- Industry
- MDU Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- MDU Industrials
- AKRO Health Care
- Exchange
- MDU Nasdaq
- AKRO Nasdaq
- Market Cap
- MDU 3.4B
- AKRO 2.8B
- IPO Year
- MDU N/A
- AKRO 2019
- Fundamental
- Price
- MDU $17.50
- AKRO $42.39
- Analyst Decision
- MDU Strong Buy
- AKRO Strong Buy
- Analyst Count
- MDU 3
- AKRO 9
- Target Price
- MDU $21.67
- AKRO $76.29
- AVG Volume (30 Days)
- MDU 1.2M
- AKRO 1.1M
- Earning Date
- MDU 05-08-2025
- AKRO 05-16-2025
- Dividend Yield
- MDU 2.61%
- AKRO N/A
- EPS Growth
- MDU N/A
- AKRO N/A
- EPS
- MDU 1.27
- AKRO N/A
- Revenue
- MDU $1,844,536,000.00
- AKRO N/A
- Revenue This Year
- MDU $10.58
- AKRO N/A
- Revenue Next Year
- MDU $3.70
- AKRO N/A
- P/E Ratio
- MDU $13.78
- AKRO N/A
- Revenue Growth
- MDU 91.83
- AKRO N/A
- 52 Week Low
- MDU $13.23
- AKRO $17.86
- 52 Week High
- MDU $20.39
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- MDU 60.44
- AKRO 52.42
- Support Level
- MDU $17.33
- AKRO $41.60
- Resistance Level
- MDU $17.56
- AKRO $46.47
- Average True Range (ATR)
- MDU 0.33
- AKRO 2.05
- MACD
- MDU 0.08
- AKRO 0.37
- Stochastic Oscillator
- MDU 75.60
- AKRO 55.60
About MDU MDU Resources Group Inc. (Holding Company)
MDU Resources Group Inc operates in three business segments, which include the electric segment, which generates, transmits, and distributes electricity in Montana, North Dakota, South Dakota, and Wyoming; The natural gas distribution segment distributes natural gas in those states, as well as in Idaho, Minnesota, Oregon, and Washington; The pipeline segment provides natural gas transportation and underground storage services through a regulated pipeline system in the Rocky Mountain and northern Great Plains regions of the United States.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.